Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam 10% in ITP
NCT00426270Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jun 2006
- Primary completion
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of human normal immunoglobulin in immune thrombocytopenic purpura (ITP), sponsored by Octapharma. Primary endpoint: Percentage of Participants With a Clinical Response. Started Jun 2006; status: completed.
02
Drugs
human normal immunoglobulin
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT00426270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00426270.